These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 24631134

  • 21. Meta-analysis of TAFI polymorphisms and risk of cardiovascular and cerebrovascular diseases.
    Wang SW, Zhang HH, Dong CY, Sun HH.
    Genet Mol Res; 2016 Apr 04; 15(2):. PubMed ID: 27173177
    [Abstract] [Full Text] [Related]

  • 22. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD).
    Verdú J, Marco P, Benlloch S, Sanchez J, Lucas J.
    Thromb Haemost; 2006 Mar 04; 95(3):585-6. PubMed ID: 16525595
    [No Abstract] [Full Text] [Related]

  • 23. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays.
    Guimarães AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC.
    Br J Haematol; 2004 Mar 04; 124(5):659-65. PubMed ID: 14871254
    [Abstract] [Full Text] [Related]

  • 24. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.
    Meltzer ME, Doggen CJ, de Groot PG, Meijers JC, Rosendaal FR, Lisman T.
    Haematologica; 2009 Jun 04; 94(6):811-8. PubMed ID: 19377074
    [Abstract] [Full Text] [Related]

  • 25. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography.
    Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP.
    Thromb Haemost; 2002 Dec 04; 88(6):1020-5. PubMed ID: 12529754
    [Abstract] [Full Text] [Related]

  • 26. A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor.
    Stanne TM, Olsson M, Lorentzen E, Pedersen A, Gummesson A, Gils A, Jood K, Engström G, Melander O, Declerck PJ, Jern C.
    Thromb Haemost; 2018 Feb 04; 118(2):298-308. PubMed ID: 29378355
    [Abstract] [Full Text] [Related]

  • 27. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study.
    de Bruijne EL, Gils A, Guimarães AH, Dippel DW, Deckers JW, van den Meiracker AH, Poldermans D, Rijken DC, Declerck PJ, de Maat MP, Leebeek FW.
    J Thromb Haemost; 2009 Jun 04; 7(6):919-27. PubMed ID: 19323787
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.
    Santamaría A, Oliver A, Borrell M, Mateo J, Belvis R, Martí-Fábregas J, Ortín R, Tirado I, Souto JC, Fontcuberta J.
    Stroke; 2003 Oct 04; 34(10):2387-91. PubMed ID: 12947154
    [Abstract] [Full Text] [Related]

  • 30. A new functional assay of thrombin activatable fibrinolysis inhibitor.
    Guimarães AH, Bertina RM, Rijken DC.
    J Thromb Haemost; 2005 Jun 04; 3(6):1284-92. PubMed ID: 15946219
    [Abstract] [Full Text] [Related]

  • 31. Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.
    Yaoita N, Satoh K, Satoh T, Sugimura K, Tatebe S, Yamamoto S, Aoki T, Miura M, Miyata S, Kawamura T, Horiuchi H, Fukumoto Y, Shimokawa H.
    Arterioscler Thromb Vasc Biol; 2016 Jun 04; 36(6):1293-301. PubMed ID: 27102961
    [Abstract] [Full Text] [Related]

  • 32. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children.
    Emonts M, de Bruijne EL, Guimarães AH, Declerck PJ, Leebeek FW, de Maat MP, Rijken DC, Hazelzet JA, Gils A.
    J Thromb Haemost; 2008 Feb 04; 6(2):268-76. PubMed ID: 18021301
    [Abstract] [Full Text] [Related]

  • 33. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
    Güldaş M, Altinkaya SÖ, Nergiz S, Demircan-Sezer S, Yüksel H.
    Gynecol Endocrinol; 2015 Jul 04; 31(7):536-9. PubMed ID: 26220768
    [Abstract] [Full Text] [Related]

  • 34. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
    Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC.
    J Thromb Haemost; 2005 Oct 04; 3(10):2211-8. PubMed ID: 16092924
    [Abstract] [Full Text] [Related]

  • 35. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients.
    Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y.
    J Clin Endocrinol Metab; 2002 Feb 04; 87(2):660-5. PubMed ID: 11836301
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The impact of single nucleotide polymorphisms of the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI antigen levels in healthy children and pediatric oncology patients.
    Knoefler R, Ludwig K, Kostka H, Kuhlisch E, Siegert G, Suttorp M.
    Semin Thromb Hemost; 2003 Dec 04; 29(6):575-83. PubMed ID: 14719174
    [Abstract] [Full Text] [Related]

  • 38. Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: analysis of a normal Japanese population.
    Akatsu H, Ishiguro M, Ogawa N, Kanesaka T, Okada N, Yamamoto T, Campbell W, Okada H.
    Microbiol Immunol; 2007 Dec 04; 51(5):507-17. PubMed ID: 17579260
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.
    Fawzy MS, Mohammed EA, Ahmed AS, Fakhr-Eldeen A.
    Meta Gene; 2015 Jun 04; 4():73-84. PubMed ID: 25893174
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.